Cargando…

Using 3D-bioprinted models to study pediatric neural crest-derived tumors

The use of three-dimensional (3D) bioprinting has remained at the forefront of tissue engineering and has recently been employed for generating bioprinted solid tumors to be used as cancer models to test therapeutics. In pediatrics, neural crest-derived tumors are the most common type of extracrania...

Descripción completa

Detalles Bibliográficos
Autores principales: Quinn, Colin H, Beierle, Andee M, Julson, Janet R, Erwin, Michael E, Alrefai, Hasan, Markert, Hooper R, Stewart, Jerry E, Hutchins, Sara Claire, Bownes, Laura V, Aye, Jamie M, Mroczek-Musulman, Elizabeth, Hicks, Patricia H, Yoon, Karina J, Willey, Christopher D, Beierle1, Elizabeth A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Whioce Publishing Pte. Ltd. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10261178/
https://www.ncbi.nlm.nih.gov/pubmed/37323483
http://dx.doi.org/10.18063/ijb.723
_version_ 1785057896819589120
author Quinn, Colin H
Beierle, Andee M
Julson, Janet R
Erwin, Michael E
Alrefai, Hasan
Markert, Hooper R
Stewart, Jerry E
Hutchins, Sara Claire
Bownes, Laura V
Aye, Jamie M
Mroczek-Musulman, Elizabeth
Hicks, Patricia H
Yoon, Karina J
Willey, Christopher D
Beierle1, Elizabeth A
author_facet Quinn, Colin H
Beierle, Andee M
Julson, Janet R
Erwin, Michael E
Alrefai, Hasan
Markert, Hooper R
Stewart, Jerry E
Hutchins, Sara Claire
Bownes, Laura V
Aye, Jamie M
Mroczek-Musulman, Elizabeth
Hicks, Patricia H
Yoon, Karina J
Willey, Christopher D
Beierle1, Elizabeth A
author_sort Quinn, Colin H
collection PubMed
description The use of three-dimensional (3D) bioprinting has remained at the forefront of tissue engineering and has recently been employed for generating bioprinted solid tumors to be used as cancer models to test therapeutics. In pediatrics, neural crest-derived tumors are the most common type of extracranial solid tumors. There are only a few tumor-specific therapies that directly target these tumors, and the lack of new therapies remains detrimental to improving the outcomes for these patients. The absence of more efficacious therapies for pediatric solid tumors, in general, may be due to the inability of the currently employed preclinical models to recapitulate the solid tumor phenotype. In this study, we utilized 3D bioprinting to generate neural crest-derived solid tumors. The bioprinted tumors consisted of cells from established cell lines and patient-derived xenograft tumors mixed with a 6% gelatin/1% sodium alginate bioink. The viability and morphology of the bioprints were analyzed via bioluminescence and immunohisto chemistry, respectively. We compared the bioprints to traditional twodimensional (2D) cell culture under conditions such as hypoxia and therapeutics. We successfully produced viable neural crest-derived tumors that retained the histology and immunostaining characteristics of the original parent tumors. The bioprinted tumors propagated in culture and grew in orthotopic murine models. Furthermore, compared to cells grown in traditional 2D culture, the bioprinted tumors were resistant to hypoxia and chemotherapeutics, suggesting that the bioprints exhibited a phenotype that is consistent with that seen clinically in solid tumors, thus potentially making this model superior to traditional 2D culture for preclinical investigations. Future applications of this technology entail the potential to rapidly print pediatric solid tumors for use in high-throughput drug studies, expediting the identification of novel, individualized therapies.
format Online
Article
Text
id pubmed-10261178
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Whioce Publishing Pte. Ltd.
record_format MEDLINE/PubMed
spelling pubmed-102611782023-06-15 Using 3D-bioprinted models to study pediatric neural crest-derived tumors Quinn, Colin H Beierle, Andee M Julson, Janet R Erwin, Michael E Alrefai, Hasan Markert, Hooper R Stewart, Jerry E Hutchins, Sara Claire Bownes, Laura V Aye, Jamie M Mroczek-Musulman, Elizabeth Hicks, Patricia H Yoon, Karina J Willey, Christopher D Beierle1, Elizabeth A Int J Bioprint Research Article The use of three-dimensional (3D) bioprinting has remained at the forefront of tissue engineering and has recently been employed for generating bioprinted solid tumors to be used as cancer models to test therapeutics. In pediatrics, neural crest-derived tumors are the most common type of extracranial solid tumors. There are only a few tumor-specific therapies that directly target these tumors, and the lack of new therapies remains detrimental to improving the outcomes for these patients. The absence of more efficacious therapies for pediatric solid tumors, in general, may be due to the inability of the currently employed preclinical models to recapitulate the solid tumor phenotype. In this study, we utilized 3D bioprinting to generate neural crest-derived solid tumors. The bioprinted tumors consisted of cells from established cell lines and patient-derived xenograft tumors mixed with a 6% gelatin/1% sodium alginate bioink. The viability and morphology of the bioprints were analyzed via bioluminescence and immunohisto chemistry, respectively. We compared the bioprints to traditional twodimensional (2D) cell culture under conditions such as hypoxia and therapeutics. We successfully produced viable neural crest-derived tumors that retained the histology and immunostaining characteristics of the original parent tumors. The bioprinted tumors propagated in culture and grew in orthotopic murine models. Furthermore, compared to cells grown in traditional 2D culture, the bioprinted tumors were resistant to hypoxia and chemotherapeutics, suggesting that the bioprints exhibited a phenotype that is consistent with that seen clinically in solid tumors, thus potentially making this model superior to traditional 2D culture for preclinical investigations. Future applications of this technology entail the potential to rapidly print pediatric solid tumors for use in high-throughput drug studies, expediting the identification of novel, individualized therapies. Whioce Publishing Pte. Ltd. 2023-03-29 /pmc/articles/PMC10261178/ /pubmed/37323483 http://dx.doi.org/10.18063/ijb.723 Text en Copyright: © 2023, Quinn CH, Beierle AM, Julson JR, et al. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, permitting distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Quinn, Colin H
Beierle, Andee M
Julson, Janet R
Erwin, Michael E
Alrefai, Hasan
Markert, Hooper R
Stewart, Jerry E
Hutchins, Sara Claire
Bownes, Laura V
Aye, Jamie M
Mroczek-Musulman, Elizabeth
Hicks, Patricia H
Yoon, Karina J
Willey, Christopher D
Beierle1, Elizabeth A
Using 3D-bioprinted models to study pediatric neural crest-derived tumors
title Using 3D-bioprinted models to study pediatric neural crest-derived tumors
title_full Using 3D-bioprinted models to study pediatric neural crest-derived tumors
title_fullStr Using 3D-bioprinted models to study pediatric neural crest-derived tumors
title_full_unstemmed Using 3D-bioprinted models to study pediatric neural crest-derived tumors
title_short Using 3D-bioprinted models to study pediatric neural crest-derived tumors
title_sort using 3d-bioprinted models to study pediatric neural crest-derived tumors
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10261178/
https://www.ncbi.nlm.nih.gov/pubmed/37323483
http://dx.doi.org/10.18063/ijb.723
work_keys_str_mv AT quinncolinh using3dbioprintedmodelstostudypediatricneuralcrestderivedtumors
AT beierleandeem using3dbioprintedmodelstostudypediatricneuralcrestderivedtumors
AT julsonjanetr using3dbioprintedmodelstostudypediatricneuralcrestderivedtumors
AT erwinmichaele using3dbioprintedmodelstostudypediatricneuralcrestderivedtumors
AT alrefaihasan using3dbioprintedmodelstostudypediatricneuralcrestderivedtumors
AT markerthooperr using3dbioprintedmodelstostudypediatricneuralcrestderivedtumors
AT stewartjerrye using3dbioprintedmodelstostudypediatricneuralcrestderivedtumors
AT hutchinssaraclaire using3dbioprintedmodelstostudypediatricneuralcrestderivedtumors
AT bowneslaurav using3dbioprintedmodelstostudypediatricneuralcrestderivedtumors
AT ayejamiem using3dbioprintedmodelstostudypediatricneuralcrestderivedtumors
AT mroczekmusulmanelizabeth using3dbioprintedmodelstostudypediatricneuralcrestderivedtumors
AT hickspatriciah using3dbioprintedmodelstostudypediatricneuralcrestderivedtumors
AT yoonkarinaj using3dbioprintedmodelstostudypediatricneuralcrestderivedtumors
AT willeychristopherd using3dbioprintedmodelstostudypediatricneuralcrestderivedtumors
AT beierle1elizabetha using3dbioprintedmodelstostudypediatricneuralcrestderivedtumors